UNSPSC 51432904: Fosinopril sodium

This classification denotes an ace inhibitor with the molecular formula C30H45NO7P.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW2RTH6T2N, chemically known as l-proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, sodium salt, (1(s*(r*)),2alpha,4beta)- but more generally known as fosinopril sodium, which bears US NIH Compound Identifier 55890.

UNSPSC 51432904 Fosinopril sodium is a Commodity code covering a specific antihypertensive pharmaceutical product in tablet or injectable form. State and local governments procure this drug through two primary channels: direct pharmaceutical supply contracts for emergency medical services, hospitals, and health departments, and participation in cooperative purchasing agreements that bundle fosinopril with broader pharmaceutical catalogs. Recent solicitations show demand concentrated in emergency response (fire rescue services acquiring Advanced Life Support Medications) and multistate health procurement programs serving state agencies, local facilities, and employee health plans.

The issuing bodies soliciting under this code span city fire departments, state health agencies, and cooperative purchasing alliances. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026 for Advanced Life Support Medications to support Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent Small Local Business Enterprise (SLBE) bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026 with a response deadline of March 26, 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026 to explore direct-to-manufacturer prescription programs and vendor capacity for supporting therapeutic pharmacy initiatives. Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with multistate cooperative purchasing as an emerging distribution model for commodity pharmaceutical procurement.